Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31156743 | 1.00 | CNR1 (0.46) | CNR1CA1CA2GLAKMT2A | |
| SCHEMBL3507902 | 0.86 | DYRK1A (0.43) | CA1CA2KMT2ANAMPTSMN1; SMN2 | |
| SCHEMBL23684240 | 0.84 | CNR1 (0.43) | CNR1CA1CA2GLAKMT2A | |
| SCHEMBL25808897 | 0.83 | CA2 (0.45) | CA1CA2KMT2AGAANQO2 | |
| SCHEMBL18041406 | 0.83 | KDM4E (0.46) | CNR1CA1CA2GLAKMT2A | |
| SCHEMBL31156763 | 0.83 | CA2 (0.45) | CA1CA2KMT2AGAANQO2 | |
| SCHEMBL6204579 | 0.80 | MTNR1A (0.58) | CNR1CA1CA2NPC1RAB9A | |
| SCHEMBL8757522 | 0.79 | GLA (0.67) | CA1CA2GLAKMT2ANPC1 | |
| SCHEMBL22068709 | 0.79 | DYRK1A (0.47) | CA1CA2GLAKMT2ANPC1 | |
| SCHEMBL1718277 | 0.78 | NQO2 (0.51) | CA1CA2NQO2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250312335-A1 | FLT COMBINATION THERAPY FOR CANCER AND COMPOSITIONS THEREFOR | BIOMEA FUSION, INC. | 2025-10-09 | — | — | US | disclosed |
| US-20250136558-A1 | PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 | BIOMEA FUSION, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4525873-A1 | FLT3 COMBINATION THERAPY FOR CANCER AND COMPOSITIONS THEREFOR | Biomea Fusion, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| US-20240262795-A1 | PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 | BIOMEA FUSION, INC. | 2024-08-08 | — | — | US | disclosed |
| EP-4392409-A1 | PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 | Biomea Fusion, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-4370506-A1 | PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 | Biomea Fusion, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-11945785-B2 | Pyrazine compounds as inhibitors of FLT3 | BIOMEA FUSION, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| WO-2023225005-A1 | FLT3 COMBINATION THERAPY FOR CANCER AND COMPOSITIONS THEREFOR | BIOMEA FUSION, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225005-A1 | FLT3 COMBINATION THERAPY FOR CANCER AND COMPOSITIONS THEREFOR | BIOMEA FUSION, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230339867-A1 | PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 | BIOMEA FUSION, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230339867-A1 | PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 | BIOMEA FUSION, INC. | 2023-10-26 | — | — | US | disclosed |
| WO-2023129667-A1 | PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 | BIOMEA FUSION, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023129667-A1 | PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 | BIOMEA FUSION, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023027966-A1 | PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 | BIOMEA FUSION, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240262795-A1 | PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 | FLT3, MCL1, CSF3R | CNR1 4579/4885CA1 4568/4885CA2 4682/4885 |
| US-20250136558-A1 | PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 | FLT3, MCL1, JAK2 | CNR1 4689/4885CA1 4305/4885CA2 4239/4885 |
| US-11945785-B2 | Pyrazine compounds as inhibitors of FLT3 | FLT3, MCL1, JAK2 | CNR1 4629/4885CA1 4571/4885CA2 4531/4885 |
| US-20230339867-A1 | PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 | FLT3, MCL1, CSF3R | CNR1 4579/4885CA1 4568/4885CA2 4682/4885 |
| US-20250312335-A1 | FLT COMBINATION THERAPY FOR CANCER AND COMPOSITIONS THEREFOR | FLT3, MEN1, FEM1B | CNR1 4842/4885CA1 4315/4885CA2 4512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.